Will the Phase 2 trial "Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)" reach primary completion on or before Sep 21, 2028?

Resolves Yes if ClinicalTrials.gov record NCT05587712 (Merck Sharp & Dohme LLC) shows an actual primary completion date on or before Sep 21, 2028. Registered date at generation: Sep 21, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Sep 21, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.